Additionally, metabolic therapies that exploit the vulnerabilities induced by MYC, such as inhibitors of glycolysis or glutaminase, have shown preclinical efficacy in MYC-driven cancers and are now being investigated in the context of ES. This evidence concerns the gene MYC and cancer.